Purdue University School of Veterinary Medicine - Anamnesis Yearbook (West Lafayette, IN)

Page 49 text:

Congratulations cmd besr wishes for continued success GRADUATING CLASS of 1983 Burns-Biotec Loborofories Subsidiary of Schering Corpororiom J Kemilworrh, NJ. 070813

Page 48 text:

may i lima E Special Diet Formulation SPECIAL DIET FOHIVIULATION, PENNSAUKEN, N.J. U81 10 609-662-74121215-928-1120

Page 50 text:

UIZ QUICK Q What should you look for first in a canine parvovirus vaccine? t challenge. Vaccine must protect agains asure of efficacy, but d Efficacy. Titer levels may be considered a me challenge is the real test! 'Vanguard' efficacy studies' showe 1000fQ of vaccinated dogs protected against challenge that produced severe clinical signs in all unvaccinated dogs. Duration. Vaccine must protect for more than a few weeks. ln a test, Norden's lVlLV CPV parvovirus vaccine provided protection as long as 1 year after vaccination. Safety. Vaccine must not cause reactions in patient. ln an extensive 7-state field trial study, 1,800 doses of 'Vanguard' were administered with exceptional safety. immunogenic. Vaccine antigens must not be immunosuppressive. ln Norden tests, no significant difference in the levels of serum antibodies was recorded between dogs vaccinated with Vanguard DA2Pl.+ CPV and those given the same vaccine without the CPV antigen. Convenience. Vaccine must not interfere with normal schedules. 'Vanguard' is available as single antigen or in combinations to fit a variety of vaccination programs. 'Norden Laboratories 19231 u '5'.9.ES!?.E,!5! PV uvii.vi v Vanguard C Vanguard DAQP + CPV Vanguard DA2PL + CP rotection you've been looking forl The parvovirus p ' 1983 Norden Laboralorves lnc PA01013 ueiiodiui ale ire Aeul HQMSNV 9 9 isuiebe uoiioetoid inq '1 ioi Aed siuaii:JinoA1euM si e6ueii u Q Q V t t t t t t tt K W, Ni ttf .tt- Q: t